Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from HBM

HBM Revenue Poised To Cross $10B as SK hynix Predicts First Double-Digit Revenue Share

Offering some rare insight into the scale of HBM memory sales – and on its growth in the face of unprecedented demand from AI accelerator vendors – the company recently disclosed that it expects HBM sales to make up "a double-digit percentage of its DRAM chip sales" this year. Which…

Memory maker SK hynix booms during AI frenzy — now controls 35% of the DRAM market

Memory maker SK hynix booms during AI frenzy — now controls 35% of the DRAM market

DRAM sales, especially for HBM, have surged on the back of the AI business frenzy, and it's been to SK Hynix's benefit.

Tom’s Hardware

RBC Capital Cuts Hudbay Minerals Price Target By 14%

RBC Capital Cuts Hudbay Minerals Price Target By 14%

RBC Capital analyst Sam Crittenden lowered the price target for HudBay Minerals Inc (TSX:HBM) (NYSE:HBM) to C$12 from C$14. The analyst maintained the Outperform rating on the shares. Crittenden stated that, despite what should be the year's weakest quarter, he continues to expect strong FCF and production growth from Hudbay in 2022. The analyst believes…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Preview: Hudbay Minerals's Earnings

Hudbay Minerals (NYSE:HBM) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Hudbay Minerals will report an earnings per share (EPS) of $0.12.

Earnings Outlook For Hudbay Minerals

Hudbay Minerals (NYSE:HBM) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Hudbay Minerals will report an earnings per share (EPS) of $0.12.

AstraZeneca Bets $25M On Preclinical Bispecific Antibody

Harbour BioMed has announced a global out-license agreement with AstraZeneca plc (NASDAQ:AZN) for CLDN18.2xCD3 bispecific antibody (HBM7022). HBM7022 is a novel bispecific antibody generated from HBM's HCAb Based Immune Cell Engagers (HBICE) Platform. HBM7022 is currently in the preclinical stage, which crosslinks tumor cells and T cells by targeting a tumor-associated antigen (Claudin18.2) and…

Why Clean Energy Demand Will Keep Copper Prices High

Copper prices are currently hovering near all-time highs due to fears of supply disruptions and low stockpiles. As the world transitions towards clean energy, the demand for copper, a widely used metal in energy generation, is expected to keep surging, leading to a further increase in its prices. Fundamentally strong…

inkl

Read news from The Economist, FT, and more,
with one subscription

Hudbay Minerals: Q4 Earnings Insights

Hudbay Minerals: Q4 Earnings Insights

Hudbay Minerals (NYSE:HBM) reported its Q4 earnings results on Wednesday, February 23, 2022 at 06:00 PM. Here's what investors need to know about the announcement.

Earnings Outlook For Hudbay Minerals

Earnings Outlook For Hudbay Minerals

Hudbay Minerals (NYSE:HBM) is set to give its latest quarterly earnings report on Wednesday, 2022-02-23. Here's what investors need to know before the announcement. Analysts estimate that Hudbay Minerals will report an earnings per share (EPS) of $0.13.

1 2

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

AstraZeneca Plc

FreeportMcMoRan Inc

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play